Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation

Shin Fukudo; Kohei Kaku

doi:10.5056/JNM19010

Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation

医学系研究科・障害科学専攻

研究成果: Letter › 査読

本文言語	English
ページ（範囲）	332-333
ページ数	2
ジャーナル	Journal of Neurogastroenterology and Motility
巻	25
号	2
DOI	https://doi.org/10.5056/JNM19010
出版ステータス	Published - 2019 4月 1

ASJC Scopus subject areas

臨床神経学
消化器病学

文献へのアクセス

10.5056/JNM19010

他のファイルとリンク

引用スタイル

@article{ebccd0cafc904e658a201575641faf0b,

title = "Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation",

author = "Shin Fukudo and Kohei Kaku",

note = "Funding Information: Financial support: This study was funded by Kissei Pharmaceutical Co, Ltd (Grant No. KWA1205). Conflicts of interest: Shin Fukudo reports grants and personal fees from Kissei Pharmaceutical, during the conduct of the study; personal fees from Dainippon Sumitomo Pharma, grants and personal fees from Abott Japan, personal fees from Scampo Pharma, grants from Ono Pharmaceutical, grants and personal fees from Astellas Pharmaceutical, personal fees from Sanwa Chemical Co. Ltd, personal fees from Zeria, personal fees from Glaxo-Smith-Kline, personal fees Funding Information: from Mochida Pharmaceutical, personal fees from Shionogi Pharmaceutical, grants and personal fees from AstraZeneca, grants from Smoking Research Foundation, grants and personal fees from Tsumu-ta Co. Ltd., personal fees and non-financial support from Miyarisan Pharmaceutical, grants from Kao Co. Ltd., and grants from Zespri Co. Ltd, outside the submitted work. Kohei Kaku reports personal fees from Kissei Pharmaceutical, during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from Daiichi Sankyo, grants and personal fees from Taisho Toyama Pharmaceutical, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Astellas Pharma, personal fees from AstraZeneca, personal fees from Sumitomo Dainippon Pharma, personal fees from Kissei Pharmaceutical, personal fees from Kowa, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Ono Pharmaceutical, and personal fees from Sanofi K.K, outside the submitted work. Author contributions: Shin Fukudo and Kohei Kaku designed, performed, and analysed the study. All authors contributed to data interpretation, writing, and final approval of the manuscript.",

year = "2019",

month = apr,

day = "1",

doi = "10.5056/JNM19010",

language = "English",

volume = "25",

pages = "332--333",

journal = "Journal of Neurogastroenterology and Motility",

issn = "2093-0879",

publisher = "Korean Society of Neurogastroenterology and Motility",

number = "2",

}

TY - JOUR

T1 - Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients with Functional Constipation

AU - Fukudo, Shin

AU - Kaku, Kohei

N1 - Funding Information: Financial support: This study was funded by Kissei Pharmaceutical Co, Ltd (Grant No. KWA1205). Conflicts of interest: Shin Fukudo reports grants and personal fees from Kissei Pharmaceutical, during the conduct of the study; personal fees from Dainippon Sumitomo Pharma, grants and personal fees from Abott Japan, personal fees from Scampo Pharma, grants from Ono Pharmaceutical, grants and personal fees from Astellas Pharmaceutical, personal fees from Sanwa Chemical Co. Ltd, personal fees from Zeria, personal fees from Glaxo-Smith-Kline, personal fees Funding Information: from Mochida Pharmaceutical, personal fees from Shionogi Pharmaceutical, grants and personal fees from AstraZeneca, grants from Smoking Research Foundation, grants and personal fees from Tsumu-ta Co. Ltd., personal fees and non-financial support from Miyarisan Pharmaceutical, grants from Kao Co. Ltd., and grants from Zespri Co. Ltd, outside the submitted work. Kohei Kaku reports personal fees from Kissei Pharmaceutical, during the conduct of the study; grants and personal fees from Boehringer Ingelheim, grants from Daiichi Sankyo, grants and personal fees from Taisho Toyama Pharmaceutical, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Takeda Pharmaceutical, grants and personal fees from Astellas Pharma, personal fees from AstraZeneca, personal fees from Sumitomo Dainippon Pharma, personal fees from Kissei Pharmaceutical, personal fees from Kowa, personal fees from MSD, personal fees from Novartis Pharma, personal fees from Ono Pharmaceutical, and personal fees from Sanofi K.K, outside the submitted work. Author contributions: Shin Fukudo and Kohei Kaku designed, performed, and analysed the study. All authors contributed to data interpretation, writing, and final approval of the manuscript.

PY - 2019/4/1

Y1 - 2019/4/1

UR - http://www.scopus.com/inward/record.url?scp=85113785369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113785369&partnerID=8YFLogxK

U2 - 10.5056/JNM19010

DO - 10.5056/JNM19010

M3 - Letter

AN - SCOPUS:85113785369

VL - 25

SP - 332

EP - 333

JO - Journal of Neurogastroenterology and Motility

JF - Journal of Neurogastroenterology and Motility

SN - 2093-0879

IS - 2

ER -